Advanced Solid Tumors | Norton Healthcare

Indication: Advanced Solid Tumors

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

Sub-indication: Miscellaneous Malignancies

Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Ascendis Pharma

Learn more at ClinicalTrials.gov

Email for more information: MISC-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.